← Tim Opler
What podcasts say about Tim Opler
Every statement, with the speaker, the exact quote and the moment it was said.
What Tim Opler has said on podcasts
5 statements · 3 positive · 1 negative · 1 mixed
AI will substantially drive efficiency in biotech.
“AI is going to be a big, big factor kind of driving efficiencies.”
Open the episode · Episode 201 - October 30, 2026Listen at 9:07
Clinical development, not target identification or design, is drug development’s main bottleneck.
“the real bottleneck in drug development isn't sort of, target identification, you know, drug design, the bottleneck is clinical development.”
Open the episode · Episode 201 - October 30, 2026Listen at 17:51
AI efficiencies will be meaningful but will not accelerate drug development by 90%.
“I think the efficiencies that it will bring. be meaningful, but more marginal and certainly not accelerate things by 90%.”
Open the episode · Episode 201 - October 30, 2026Listen at 18:23
Atsuka’s sibeprenlimab stopped IgA-nephropathy progression in the study.
“this drug stopped disease progression”
Open the episode · Episode 201 - October 30, 2026Listen at 39:39
Sibeprenlimab produced one kidney event versus 28 with placebo.
“one kidney event on treatment versus 28. on placebo.”
Open the episode · Episode 201 - October 30, 2026Listen at 40:03
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.